Euronext Amsterdam

ONWARD® Medical Successfully Raises €20 Million in a Capital Increase by Way of an Accelerated Bookbuild Offering and by Way of a Public Offering in France

Retrieved on: 
Thursday, March 21, 2024
Offerings, Public, Private, Brussels Stock Exchange, KBC, Euronext, DSM-IV codes, CSO, Euronext Amsterdam, NOT, SCI, Movement, Hand, Security (finance)

PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.

Key Points: 
  • PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.
  • “We are delighted to announce the successful capital raise of €20 million, including a fully subscribed upsize option despite challenging market conditions,” said Dave Marver, CEO of ONWARD Medical.
  • Existing shareholders participated in the deal with an aggregate of 333,333 shares and 333,333 shares respectively allocated to INKEF Capital and EQT Life Sciences.
  • Following the Offerings, INKEF Capital and EQT Life Sciences will respectively hold 11.5% and 11.2% of the Company’s share capital.

VEON 4Q23 trading update: Strong organic growth in revenue and EBITDA, solid execution of VEON 2.0 strategy

Retrieved on: 
Thursday, March 21, 2024
VEON, Growth, Health, FY, Education, Capital expenditure, Yoy, Euronext Amsterdam, USD, HQ, Total, LTM, Cryptocurrency

In 4Q23, VEON continued to report growth in revenues in reported currency terms with double digit local currency top-line growth.

Key Points: 
  • In 4Q23, VEON continued to report growth in revenues in reported currency terms with double digit local currency top-line growth.
  • Total revenues reached USD 953 million, an increase of 1.4% YoY in reported currency (+17.9% YoY in local currency normalised for one-offs).
  • VEON has announced its full-year revenue guidance of 16-18% growth in local currency, EBITDA guidance of 18%-20% growth, and outlook for the Group’s capex intensity for 2024 year at 18%-19%.
  • We are pleased to guide the market for continued strong and profitable growth in 2024, maintaining our focus on financial discipline and balance sheet management.”

ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild Offering and of a Public Offering in France for an Indicative Amount of EUR 15 Million, with an Up to EUR 5 Million Upsize Option

Retrieved on: 
Wednesday, March 20, 2024
Brussels Stock Exchange, SCI, Public, Private, KBC, VWAP, ARC, Hand, Acceleration, Regulation, DSM-IV codes, CSO, Movement, EUR, Private placement, BCI, Offerings, Public offering, Equity carve-out, Euronext, Issue, Euronext Amsterdam, Security (finance)

The final number of New Shares placed and the issue price per New Share (the “Issue Price”) will be announced after pricing of the Offerings.

Key Points: 
  • The final number of New Shares placed and the issue price per New Share (the “Issue Price”) will be announced after pricing of the Offerings.
  • The New Shares will be issued from the Company’s authorized capital under exclusion of the existing shareholders’ pre-emptive rights.
  • “It is the Company’s intention to raise gross proceeds of indicatively EUR 15 million from the Offerings, with an up to EUR 5 million upsize option.
  • A separate announcement will be made shortly regarding the Public Offer in France via the PrimaryBid platform and its terms.

ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild Offering and of a Public Offering in France for an Indicative Amount of EUR 15 Million, with an Up to EUR 5 Million Upsize Option

Retrieved on: 
Wednesday, March 20, 2024
Failure, Economy, Brussels Stock Exchange, Exercise, Patient, Risk, European, Intellectual property, Marketing, SCI, Annual, Public, Private, KBC, AFM, Prospectus, Royal Victorian Order, VWAP, ARC, Hand, Acceleration, Part, Research, Classification, Enrollment, Certification, DSM-IV codes, CSO, FDA, Movement, Engineering, EUR, Private placement, BCI, Offerings, Public offering, Market, Issue, Euronext Amsterdam, Probability, Security (finance)

The Issue Price will be determined by the accelerated book-building initiated with institutional investors.

Key Points: 
  • The Issue Price will be determined by the accelerated book-building initiated with institutional investors.
  • The Public Offering will not extent to retail investors located outside of France.
  • The New Shares will be issued from the Company’s authorized capital under exclusion of the existing shareholders’ pre-emptive rights.
  • It is the Company’s intention to raise gross proceeds of approximately €15.0 million from the Offerings, with an up to €5 million upsize option.

Aegon calls EUR 700 million of fixed-to-floating subordinated notes

Retrieved on: 
Tuesday, March 19, 2024
EUR, Euronext Amsterdam, Citibank, Security (finance)

The Hague, March 19, 2024 - Aegon today announces it is exercising its right to redeem EUR 700 million of 4% fixed-to-floating subordinated notes.

Key Points: 
  • The Hague, March 19, 2024 - Aegon today announces it is exercising its right to redeem EUR 700 million of 4% fixed-to-floating subordinated notes.
  • The redemption of these grandfathered Tier 2 securities will be effective as of April 25, 2024, when the aggregate principal amount of EUR 700 million will be repaid, together with any accrued and unpaid interest.
  • As previously announced, Aegon intends to refinance the notes.
  • A notice of redemption will be sent to all currently registered holders of the notes by the fiscal agent, Citibank N.A., London Branch.

Banglalink Gets Unified Licence to Deliver Superior Digital Services in Bangladesh

Retrieved on: 
Monday, March 18, 2024
VEON, Euronext Amsterdam, Bangladesh Telecommunication Regulatory Commission, Government, BTRC, Cryptocurrency

Amsterdam and Dhaka, 18 March 2024: VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, announces that Banglalink, its leading innovative digital service provider in Bangladesh, has received a unified licence from the Bangladesh Telecommunication Regulatory Commission (BTRC).

Key Points: 
  • Amsterdam and Dhaka, 18 March 2024: VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, announces that Banglalink, its leading innovative digital service provider in Bangladesh, has received a unified licence from the Bangladesh Telecommunication Regulatory Commission (BTRC).
  • “The unified licence frees up capacity for Banglalink to deliver superior digital services, enhance connectivity to its customers and streamline the user experience that it provides.
  • “As we award Banglalink the unified licence, we step closer to our goal of a streamlined telecom sector for a Smart Bangladesh.
  • Erik Aas, Chief Executive Officer of Banglalink, received the unified licence from Engineer Md Mohiuddin Ahmed, Chairman of the BTRC in Dhaka on 14 March 2024.

VEON appoints PwC as 2023 auditors, provides updates on reporting timelines

Retrieved on: 
Thursday, March 14, 2024
ISA, VEON, Annual report, International standard, Bank statement, Market, International Standards on Auditing, PCAOB, RCF, Euronext Amsterdam, Audit

The delays arise from the difficulties that the Company has faced in identifying a suitable auditor due to the material changes in the Group’s portfolio of assets.

Key Points: 
  • The delays arise from the difficulties that the Company has faced in identifying a suitable auditor due to the material changes in the Group’s portfolio of assets.
  • A suitable auditor that is qualified to provide these services in the countries where VEON operates has not yet been identified.
  • The Company will provide further updates in the future on its progress and the status of the matters mentioned herein.
  • As previously announced, VEON will release its unaudited selected financial and operating results for the fourth quarter and the twelve months ended December 31, 2023 on March 21, 2024.

Pharming Group reports fourth quarter and full year 2023 financial results

Retrieved on: 
Thursday, March 14, 2024
Patient, Health care, Epidemiology, Executive Committee, Laboratory, Microsoft Access, Lymphocyte, Clinical trial, European Commission, APDS, MHLW, AEG, Welfare, Ageing, Committee, EMA, Trial of the century, PID, CTLA4, Safety, Pharmacokinetics, Ministry, CHMP, ODD, U.S. FDA, Prevalence, PTEN, Disease, HAE, Immunodeficiency, VUS, Literature, PIK3R1, PMDA, FDA, DSM-IV codes, Diagnosis, Civil service commission, IRP, Haploinsufficiency, Genetic testing, MAA, Autoimmunity, World Games, Iberian languages, Marketing, MHRA, Euronext Amsterdam, PIK3CD, Physician, Pharmaceutical industry

The U.S. market contributed 97% of 2023 revenues, while the EU and Rest of World contributed 3%.

Key Points: 
  • The U.S. market contributed 97% of 2023 revenues, while the EU and Rest of World contributed 3%.
  • Revenues increased to US$7.9 million in the fourth quarter of 2023, driven by the continued increase in patients on paid therapy, and revenues were US$18.2 million for 2023.
  • Pharming made continued progress in the fourth quarter of 2023 on leniolisib regulatory filings for APDS patients 12 years of age and older in key global markets.
  • Pharming filed regulatory submissions in Canada and Australia in the third quarter of 2023, and Israel in the second quarter.

BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers

Retrieved on: 
Monday, March 25, 2024
Professional Services, Health, Finance, Clinical Trials, Research, Science, Pharmaceutical, PDE10, Phases of clinical research, Ulcerative colitis, Brain, IL6, Disease, Tumor necrosis factor, Central nervous system, IL8, Benevolence, Patient, CNS, CGMP, UC, Camp, Șaeș, Trial of the century, BAI, Cytokine, Drug development, Safety, Inflammatory bowel disease, Euronext Amsterdam, Steroid, JAK, Pharmaceutical industry

BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces positive safety data from its Phase Ia, first-in-human, clinical study of BEN-8744 in healthy volunteers.

Key Points: 
  • BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces positive safety data from its Phase Ia, first-in-human, clinical study of BEN-8744 in healthy volunteers.
  • As a result, BenevolentAI’s scientists designed BEN-8744 to be not only a potent PDE10 inhibitor, but also a peripherally-restricted molecule, i.e.
  • The Phase Ia study results support this profile, showing no evidence of CNS-associated adverse events at any dose level.
  • It is anticipated that the full results from this study will be presented in a peer-reviewed forum at a later date.

BM3EAC Corp. Term Sheet with Arkon Energy

Retrieved on: 
Friday, March 22, 2024
Technology, Finance, Fintech, Other Energy, Other Technology, Professional Services, Blockchain, Energy, Cryptocurrency, Electricity, Letter, Cayman Islands, Business, Sale, Arkon, EEA, Euronext Amsterdam, Person, Security (finance)

BM3EAC Corp. (the “Company”), a shell company incorporated under the laws of the Cayman Islands as an exempted company with limited liability and listed on Euronext Amsterdam, the regulated market operated by Euronext Amsterdam N.V., announces that on 21 February 2024 it entered into a term sheet (the “Terms”) with Arkon Energy Ohio LLC (now Arkon Energy US Holdco LLC) (“Arkon”) relating to a potential transaction, including a business combination, with Arkon or an entity to be formed by it or its members for such purpose (the “Potential Business Combination”).

Key Points: 
  • BM3EAC Corp. (the “Company”), a shell company incorporated under the laws of the Cayman Islands as an exempted company with limited liability and listed on Euronext Amsterdam, the regulated market operated by Euronext Amsterdam N.V., announces that on 21 February 2024 it entered into a term sheet (the “Terms”) with Arkon Energy Ohio LLC (now Arkon Energy US Holdco LLC) (“Arkon”) relating to a potential transaction, including a business combination, with Arkon or an entity to be formed by it or its members for such purpose (the “Potential Business Combination”).
  • Arkon currently has 117 megawatts (“MW”) of approved operating capacity across two data centers, including a 95MW flagship facility in Hannibal, Ohio, and a 22MW facility in Hopedale, Ohio.
  • Arkon has signed a letter of intent to acquire an additional 100MW of further pipeline capacity within these same sites.
  • Securities may not be offered, sold or otherwise transferred within the United States absent registration under the Securities Act or an exemption therefrom.